CRISPR/Cas Tau Biosensor Cells for Genetic Vulnerability Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective strategies for identifying genetic vulnerabilities associated with tau aggregation, which is a key factor in neurodegenerative diseases such as Alzheimer's and Parkinson's, limiting therapeutic intervention and understanding disease progression.
Innovation Solution
Development of Cas-tau biosensor cells and CRISPR/Cas synergistic activation mediator (SAM)-tau biosensor cells that utilize CRISPR nuclease and CRISPR activation libraries to screen for genes exhibiting synthetic lethality with tau protein aggregates, employing tau repeat domains and fluorescent reporters to monitor aggregation and assess gene function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CRISPR/Cas9 screening is used to identify genetic vulnerabilities, then therapeutic intervention strategies improve, but the complexity of the screening platform increases
Solution Approach 1:
The screening platform is divided into distinct functional modules: (1) biosensor cell generation module for creating Agg+ and Agg- cell populations, (2) CRISPR/Cas9 library transduction module for introducing guide RNAs, (3) FRET-based aggregation detection module for monitoring tau aggregates, and (4) guide RNA depletion analysis module for identifying genetic vulnerabilities. This segmentation allows each module to be optimized and maintained independently while working together to resolve the contradiction between screening reliability and platform complexity.
Solution Approach 2:
The patent introduces FRET-based fluorescent reporters as intermediaries between tau protein aggregates and the detection system. The FRET pair (donor and acceptor fluorophores) provides a quantitative, high-resolution readout of aggregation states, enabling reliable differentiation between Agg+ and Agg- cells. This intermediary measurement system enhances the reliability of genetic vulnerability identification without requiring complex direct observation methods.
2Reliability
If guide RNA depletion analysis is performed over time, then identification of synthetic lethality improves, but the time required for screening increases
Solution Approach 1:
The patent performs preliminary generation and characterization of biosensor cell populations (Agg+ and Agg-) before initiating the CRISPR/Cas9 screening. These pre-prepared cell lines with stable aggregation phenotypes serve as ready-to-use models that eliminate the need for time-consuming aggregation induction during the screening process. The preliminary establishment of FRET-based detection systems and guide RNA libraries further prepares the platform to execute rapid depletion analysis over reduced time courses.
Solution Approach 2:
The screening methodology implements continuous monitoring of guide RNA depletion across multiple time points, allowing dynamic tracking of synthetic lethality effects. By performing FRET-based aggregation assays and guide RNA quantification at sequential time points, the system continuously identifies genes with time-dependent depletion patterns, enhancing the reliability of synthetic lethality identification while optimizing the time course through efficient parallel processing of multiple samples.
3Measurement precision
If FRET-based tau aggregation monitoring is used, then measurement precision of aggregation state improves, but the device complexity increases
Solution Approach 1:
The patent merges multiple functions into the biosensor cell system: (1) tau protein expression, (2) FRET-based aggregation sensing, (3) CRISPR/Cas9 component expression, and (4) guide RNA processing all occur within a single integrated cell platform. The FRET pair is fused to tau repeat domains, allowing the same protein structure to serve both as the aggregation substrate and as the FRET-based sensor. This merging approach achieves high measurement precision for aggregation states while minimizing the cumulative complexity that would arise from separate detection systems.
Solution Approach 2:
The FRET-based detection system utilizes fluorescent color changes to report aggregation states. The donor fluorophore (e.g., cyan fluorescent protein) and acceptor fluorophore (e.g., yellow fluorescent protein) exhibit characteristic emission colors that change based on FRET efficiency. When tau aggregates form, the FRET interaction causes a measurable shift in fluorescence emission spectrum, providing a precise, visually distinguishable signal for aggregation detection without requiring complex instrumentation beyond standard flow cytometry or microscopy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the identification of genetic vulnerabilities and pathways contributing to tau-associated cell toxicity, providing insights into neurodegenerative disease mechanisms and potential therapeutic targets.
Implementation Method 1
introducing into each population of cells a library comprising a plurality of unique guide RNAs that target a plurality of genes, wherein the plurality of unique guide RNAs form complexes with the Cas protein, and the Cas protein cleaves the plurality of genes resulting in knockout of gene function
Implementation Method 2
abnormal aggregation or fibrillization of proteins is a defining feature of many diseases, notably including a number of neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD)
Implementation Method 3
a first tau repeat domain linked to a first reporter, and a second tau repeat domain linked to a second reporter, wherein in the aggregation-positive population of cells the first tau repeat domain linked to the first reporter and the second tau repeat domain linked to the second reporter stably present in an aggregated state
Data Source
AI summary
Cas-protein-ready tau biosensor cells, CRISPR/Cas synergistic activation mediator (SAM)-ready tau biosensor cells, and methods of making and using such cells to screen for genetic vulnerability associated with tau aggregation are provided.